A Phase I, Randomized, Subject And Investigator Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers
Latest Information Update: 22 Nov 2019
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 25 Jan 2012 New trial record